- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05624255
Correlating the Measure of Retinal Vascular Density Through Angio-OCT with Calcium Score (ANOSCA)
November 14, 2024 updated by: Centre Hospitalier Universitaire de Besancon
Recent case-control studies have proven that the retinal vascularization mirrors the cardiac vascularization: more the coronary network is altered, more the density of retinal vessels is reduced.
No studies have yet been realised in primary prevention.
This study aims to demonstrate a link between the density of the retinal vascularization and the calcium score, which is currently the gold standard for the classification of cardiovascular risk in primary prevention.
Thus, a simple image of the retinal vascularization could predict the cardiovascular risk of a patient.
OCT angiography would become a major aid in the classification of cardiovascular risk in asymptomatic patients.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
101
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Besançon, France, 25000
- CHU de Besançon
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Patients eligible for a calcium score as part of their standard treatment and volunteers for an ophthalmologic consultation
Exclusion Criteria:
- Pregnant women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ophthalmology consultation
Patients eligible to calcium score will be offered an ophthalmologic consultation including Angio-Optical Coherence Tomography [OCT]
|
Complete ophthalmologic examination including angio-OCT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between retinal vascular density and calcium score
Time Frame: Day 1
|
Comparison between values of calcium score and presence of vascular abnormalities in retina. Calcium is scored as follows:
|
Day 1
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2022
Primary Completion (Actual)
March 16, 2023
Study Completion (Actual)
March 16, 2023
Study Registration Dates
First Submitted
November 14, 2022
First Submitted That Met QC Criteria
November 14, 2022
First Posted (Actual)
November 22, 2022
Study Record Updates
Last Update Posted (Estimated)
November 18, 2024
Last Update Submitted That Met QC Criteria
November 14, 2024
Last Verified
November 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022/701
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vascular Diseases
-
Leiden University Medical CenterRecruitingVascular Disease,PeripheralNetherlands
-
Boston Scientific CorporationRecruitingPeripheral Vascular DiseasesUnited States, Australia, Taiwan, Thailand, Austria, Germany, Canada, France, China, Spain, Poland
-
Midwest Cardiovascular Research FoundationCompletedPeripheral Vascular DiseaseUnited States
-
W.L.Gore & AssociatesActive, not recruitingPeripheral Vascular DiseasesGermany, Netherlands, France, Italy, Spain
-
The Methodist Hospital Research InstituteNational Heart, Lung, and Blood Institute (NHLBI)RecruitingPeripheral Vascular DiseasesUnited States
-
SensomeCompletedPeripheral Vascular DiseaseBelgium
-
Hull University Teaching Hospitals NHS TrustUniversity of HullActive, not recruitingPeripheral Vascular DiseaseUnited Kingdom
-
Rijnstate HospitalCompletedPeripheral Vascular DiseasesNetherlands
-
AmgenCompletedChorioretinal Vascular DiseaseUnited States
-
Duke UniversityTerminatedRetinal Vascular DiseaseUnited States
Clinical Trials on Ophthalmologic consultation
-
Fondation Ophtalmologique Adolphe de RothschildCompletedCovid19 | Sars-CoV2France
-
Hanyang UniversityCompletedChronic Kidney Diseases | Hemolysis
-
Fondation Ophtalmologique Adolphe de RothschildCompletedCOVID19 | OphthalmopathyFrance
-
The First Affiliated Hospital of Zhengzhou UniversityCompleted
-
Fondation Ophtalmologique Adolphe de RothschildCompletedDiabetic RetinopathyFrance
-
Fondation Ophtalmologique Adolphe de RothschildCompleted
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Akdeniz UniversityCompleted
-
Akdeniz UniversityCompletedCachexia | UnderweightTurkey
-
Centre Hospitalier Universitaire de NiceCompleted